GlaxoSmithKline plc Gives Up On Cancer

Why would GlaxoSmithKline plc (LON:GSK) divest its oncology division?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Perhaps it is just a symptom of my advancing decrepitude, but I seem to hear more about cancer every year. Rarely does a season seem to pass without a cancer diagnosis or treatment cropping up among my wider friends and family, sadly.

While the prognosis for many cancers has been getting better – not least thanks to early diagnosis via screening – news that you have the disease must rank among the grimmest you can hear from your doctor. And worldwide, the total number of new cancer cases a year is expected to surge by 70% over the next 20 years to 25 million a year, according to the World Health Organisation.

By any measure, then, this is a serious disease with potentially devastating consequences that’s becoming more commonly diagnosed.

So why would GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), one of the world’s largest pharmaceutical companies, want to get out of the business of treating it?

Cash for cancer drugs

Glaxo has turned away from treating cancer – oncology, to give it its proper medical term – as a result of an £11 billion deal with Novartis announced this week.

gskThe two companies are swapping chunks of their product lines and businesses – as well as some cash – with Glaxo getting Novartis’ vaccine business, and the Swiss company taking ownership of Glaxo’s cancer drugs.

The cash element will enable Glaxo to make a special capital return of £4 billion to shareholders — so that’s one reason to do the deal. 

But the main issue is focus.

14th isn’t good enough

GlaxoSmithKline has made some decent progress with its oncology research recently.

Earlier this year it won approval for combination use of its Mekinist and Tafinlar drugs in the treatment of melanomas (skin cancers). Analysts also like Votrient, a new-ish Glaxo drug for the treatment of cancer in the kidneys and soft tissues, and the British drug maker has other promising treatments in its development pipeline.

GlaxoSmithKlineHowever, Glaxo is ranked merely 14th in the world for oncology and the pharma giants are increasingly trying to dominate their niches to increase efficiencies. It sounds grubby to talk about it in healthcare, but on one level the drugs business is just like any other – with size and specialisation come economies of scale and extra synergies.

Moreover, while GlaxoSmithKline isn’t relinquishing all its oncology research – it says it will continue to research cancer immunotherapy and epigenetics – the move does crystalize the value of most of its pipeline.

For its part, Novartis is betting it can do better at selling, distributing and developing the acquired drugs than Glaxo might have, and that this justifies paying up for them today.

Remember that Glaxo has picked up Novartis’ vaccine business as part of this deal. Glaxo was already the world’s top vaccine player, and this cements its position in a market that’s expected to grow at 10% per annum for the next decade.

Glaxo will now have more than 20 new vaccines in development, and it will acquire Novartis’ manufacturing facilities in India and China – attractive emerging markets that Glaxo is keen to tap into. It also picks up extra packaging facilities in Germany and Italy.

Show shareholders the money

Glaxo’s own numbers suggest the deal could overall add £1.3 billion to revenues on a pro-forma basis, and cost savings of as much as £1 billion a year within five years. These are big numbers, even for an £80 billion mega-company.

And the bottom line is, well, the bottom line.

While healthcare remains a sector with massive long-term potential, in the short term a focus on austerity in Europe and industry reform in the US look like curbing growth for the foreseeable future.

In addition, shareholders have grown fed up with the uncertain returns from R&D from the big pharma companies, especially with a new breed of players typified by Valeant Pharmaceuticals Intl in the US having made a string of deals that appear to have unlocked some big profits languishing hidden in the sector.

The product swap with Novartis sees Glaxo doing this sort of restructuring itself and I think it is good news for shareholders. We must hope that moving Glaxo’s cancer treatments to the specialists in Switzerland proves to be good news for cancer patients, too.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Owain owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »